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Objective: Patients with head and neck cancer frequently present to academic tertiary referral centers with
imaging studies that have been performed and interpreted elsewhere. At our institution, these outside head and
neck imaging studies undergo formal second opinion reporting by a fellowship-trained academic neuroradiologist
with expertise in head and neck imaging. The purpose of this study was to determine the impact of this practice
on cancer staging and patient management.
Methods: Our institutional review board approved the retrospective review of randomized original and second
opinion reports for 94 consecutive cases of biopsy proven or clinically suspected head and neck cancer in calendar
year 2010. Discrepancy rates for staging and recommended patient management were calculated and, for the 32%
(30/94) of cases that subsequently went to surgery, the accuracies of the reports were determined relative to the
pathologic staging gold standard.
Results: Following neuroradiologist second opinion review, the cancer stage changed in 56% (53/94) of cases and
the recommended management changed in 38% (36/94) of patients with head and neck cancer. When compared
to the pathologic staging gold standard, the second opinion was correct 93% (28/30) of the time.
Conclusion: In a majority of patients with head and neck cancer, neuroradiologist second opinion review of their
outside imaging studies resulted in an accurate change in their cancer stage and this frequently led to a change in
their management plan.
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Despite advances in diagnosis and treatment, head and
neck cancer remains an important cause of death and
disability worldwide. The most recent global estimates
from the World Health Organization indicate that
845,000 new cases of head and neck cancer are diag-
nosed each year, with a mortality rate approaching
50% [1].
Head and neck cancer may present with a variety of
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reproduction in any medium, provided the orthe primary tumor. The diagnosis is usually made or
suspected on the basis of the clinical examination and
confirmed with a biopsy of the primary lesion or a
metastatic lymph node. The most important prognos-
tic factor, after primary site, tumor type, and tumor
grade, is cancer stage and, all else being equal, high-
stage cancers have a poorer prognosis than low-stage
cancers. Cancer stage is also a major consideration
when determining appropriate treatment. For example,
for some primaries, the recommended management is
surgical for low-stage cancers and nonsurgical (e.g.
chemoradiotherapy) for high-stage cancers. Because
the primary site is usually identified clinically, and the
tumor type and grade are determined by pathology,
the main role of imaging in the initial management ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient and tumor characteristics
All cases Surgical cases
Variable (n = 94) (n = 30)
Age (y), mean (range) 61.6 (31.1, 90.1) 65.2 (36.3, 89.7)
Gender (M:F) 70:24 17:13
Primary
Oral Cavity 24 (25.5%) 19 (63.3%)
Oropharynx 22 (23.4%) 2 (6.7%)
Hypopharynx 2 (2.1%) 0 (0.0%)
Larynx 15 (16.0%) 3 (10.0%)
Salivary Gland 6 (6.4%) 3 (10.0%)
NC & PNS 5 (5.3%) 2 (6.7%)
Nasopharynx 7 (7.4%) 0 (0.0%)
Thyroid 1 (1.1%) 0 (0.0%)
Unknown 5 (5.3%) 0 (0.0%)
Skin 4 (4.3%) 1 (3.3%)
Lymphoma 3 (3.2%) 0 (0.0%)
Stage
Benign 2 (2.1%) 1 (3.3%)
Stage 0 3 (3.2%) 2 (6.7%)
Stage I 9 (9.6%) 4 (13.3%)
Stage II 3 (3.2%) 2 (6.7%)
Stage III 9 (9.6%) 3 (10.0%)
Stage IV 68 (72.3%) 18 (60.0%)
NC & PNS, Nasal Cavity and Paranasal Sinuses.
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accurate staging.
At academic tertiary referral centers, patients fre-
quently present with imaging studies that have been
performed and interpreted elsewhere [2]. At our institu-
tion, all outside head and neck imaging studies undergo
formal reinterpretation by a fellowship-trained academic
neuroradiologist with expertise in head and neck im-
aging prior to discussion of the case at a weekly multi-
disciplinary tumor board. At the weekly tumor board,
the multidisciplinary team reviews the clinical, patho-
logical, and imaging data, the cancer stage is determined,
and a treatment recommendation is made. The purpose
of this study was to determine how frequently the neu-
roradiology second opinion changed staging and man-
agement, and to estimate how frequently the second
opinion was accurate when compared with surgical
findings.
Methods
Our institutional review board (The University of
Calgary Conjoint Health Research Ethics Board) ap-
proved the retrospective review of patient data for
this study, and waived the requirement for informed
consent. All cases (n = 94) of biopsy proven or clinic-
ally suspected head and neck cancer presenting to
our academic tertiary referral center with outside
computed tomography (CT) or magnetic resonance
(MR) imaging during the 2010 calendar year were
retrospectively identified from our institutional head
and neck cancer database (Table 1). As part of our
routine practice, a fellowship-trained academic neu-
roradiologist with expertise in head and neck imaging
and three years of post-fellowship experience had is-
sued a formal second opinion report in all cases.
Hardcopies of the original and second opinion re-
ports were collected, randomized, and distributed to
three reviewers: a fellowship-trained academic head
and neck surgeon with 20 years of post-fellowship
experience, an otolaryngology-head and neck surgery
resident with four years of residency experience, and
a fellowship-trained academic neuroradiologist with
15 years of post-fellowship experience (a different
neuroradiologist than the one who had issued the
second opinion reports).
The three reviewers independently analyzed each of
the 188 randomized reports (94 original radiology re-
ports and 94 second opinion reports) and recorded the
primary site, T-category (extent of primary tumor), and
N-category (extent of cervical lymph node metastases)
using the most recent American Joint Committee on
Cancer definitions [3], as could be determined from the
information found in each radiology report. To deter-
mine the reliability of the data, the inter-rater agreementsfor T-category and N-category for the original and second
opinion reports were calculated using Fleiss' κ for multiple
raters [4]; the opinion of the head and neck surgeon was
considered the gold standard.
The cancer stage (‘Stage 0-IV’) was calculated from
the T-category and N-category data according to the
most recent American Joint Committee on Cancer
definitions [3], as all patients had no evidence of dis-
tant metastases. Staging data were then dichotomized
into low-stage (Stage 0, I, or II) vs. high-stage (Stage
III or IV) groups (‘Low/High Stage’), and into node-
negative (N0) vs. node-positive (N1, N2, or N3)
groups (‘Node Negative/Positive’). The staging data
derived from the original reports were compared
with those from the second opinion reports, and dis-
crepancy rates with 95% confidence intervals (95%
CI) were calculated using the modified Wald method
[5]. If there was a change in staging from the original
report to the second opinion, the direction of change
(up-staging vs. down-staging) was determined.
The head and neck surgeon also made a recommenda-
tion for patient management based on the information
provided in each radiology report. He was asked, “As-
suming that the information in the radiology report is
Table 2 Discrepancies in cancer staging between the
original and second opinion radiology reports
All cases Surgical cases
Staging criteria (n = 94) (n = 30)
T-category 62 (66.0%) 18 (60.0%)
N-category 50 (53.2%) 13 (43.3%)
Stage (0-IV) 53 (56.4%) 17 (56.7%)
Low/High Stage 32 (34.0%) 11 (36.7%)
Node Negative/Positive 32 (34.0%) 9 (30.0%)
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that the patient is agreeable, otherwise healthy, and has
no contraindications, what initial management would
you recommend?” His choices were: (a) surgery (resec-
tion of the primary tumor +/−lymph node dissection);
(b) radiotherapy (+/−chemotherapy); (c) no treatment;
and (d) don't know. For the ‘don’t know’ cases, the sur-
geon recorded the reason. The surgeon’s management
recommendations based on the original reports were
compared with those based on the second opinion re-
ports, and discrepancy rates with 95% confidence inter-
vals (95% CI) were calculated using the modified Wald
method [5]. Fisher’s exact test [6] was used to reject the
null hypothesis that the surgeon’s management recom-
mendations based on the original and second opinion
reports were the same.
For the subgroup of cases (n = 30) in which surgery
was subsequently performed, pathologic staging data
were acquired from pathology reports. The radiologic
staging data were compared to the pathologic staging
data and the accuracies of the original and second opin-
ion reports were calculated. Fisher’s exact test [6] was
used to reject the null hypothesis that the accuracies for
cancer stage of the original and second opinion reports
were the same.
All tests were two-sided tests using a threshold for
statistical significance of P < .05. Statistical analysis
was performed using Stata 11 (StataCorp, College Sta-
tion, TX).
Results
The staging data that were extracted from the radiology
reports were found to be reliable. There was ‘moderate’
to ‘substantial’ inter-rater agreement for the original
reports (κ = 0.44 for T-category and κ = 0.78 for N-
category) and ‘substantial’ to ‘almost perfect’ agreement
for the second opinion reports (κ = 0.62 for T-category
and κ = 0.89 for N-category) [7].
The discrepancy rate for cancer stage (Stage 0-IV) was
56.4% (95% CI, 46.3% − 65.9%); the discrepancy rates for
staging ranged from a low of 34.0% (95% CI, 25.2% −
44.1%) for both Low/High Stage and Node Negative/
Positive to a high of 66.0% (95% CI, 55.9% − 74.8%) for
T-category (Table 2). Up-staging was common, occur-
ring in 90.6% (48/53; 95% CI, 79.3% − 96.3%) of discrep-
ant cases.
Pathologic staging data were available for the 30/94
(31.9%) of cases in which surgery was subsequently
performed (Table 3). When compared to the entire
group, the surgical subgroup had a higher proportion
of oral cavity primaries and a lower proportion of oro-
pharyngeal primaries (Table 1), which reflects the fact
that oral cavity cancers are usually treated surgically
while oropharyngeal cancers are usually treated withradiotherapy +/−chemotherapy at our institution. In
the surgical cases, the original radiology reports
agreed with the pathologic stage (Stage 0-IV) 40.0%
(12/30) of the time (Table 4) whereas the second
opinion reports agreed with the pathologic stage
93.3% (28/30) of the time (P < .001). Following the
second opinion, the cancer stage changed in 56.7%
(17/30) of the surgical cases, and these changes were
pathologically proven to be correct 94.1% (16/17) of
the time (Figure 1).
The discrepancy rate for patient management was
38.3% (36/94; 95% CI, 29.1% − 48.4%); most changes
(77.8%; 28/36) were from ‘don’t know’ based on the ori-
ginal report to one of surgery or radiotherapy
(+/−chemotherapy) based on the second opinion report
(Table 5). It was not possible for the surgeon to make a
management recommendation based on either the ori-
ginal report or the second opinion report in 29.8% (28/
94) of cases. In most of these cases (75.0%; 21/28), this
was because of a technically inadequate or incomplete
scan for which the radiologist recommended additional
imaging, or a post-treatment recurrence for which the
surgeon needed details of prior treatment before making
a treatment decision. Despite this, the management rec-
ommendation based on the second opinion reports
agreed with the actual management 60.0% (18/30; 95%
CI, 42.3% − 75.4%) of the time, as compared to 33.3%
(10/30; 95% CI, 19.1% − 51.3%) of the time for the ori-
ginal reports (P = .069).
Discussion
Our study demonstrates the value of reinterpretation of
head and neck imaging studies by a fellowship-trained
academic neuroradiologist; such reinterpretation led to
more accurate staging and better treatment decision-
making. We found that, following formal second opinion
reporting of outside imaging studies, there was a change
in cancer stage in 56% of cases, resulting in a change in
management in 38% of patients; for the surgical cases,
the second opinions were pathologically proven to be
correct 93% of the time.
These findings add to the evidence that subspecialty
radiologist interpretation of imaging studies has a
Table 3 Cancer staging and recommended management based on the original and se1cond opinion radiology reports
compared to the pathologic staging gold standard (n = 30)
Staging Management
Pt Age M/F Primary Original Second opinion Pathologic Original Second opinion Actual
A 89 F Oral Cavity TxN0 T4aN2b T4aN0 Don’t know† Surgery Surgery
B 55 M Oral Cavity T0N0 T1N1 T2N1 No treatment Surgery Surgery
C 84 F Oral Cavity T2N0 T2N0 T2N2b Surgery Surgery Surgery
D 40 M NC & PNS T0N0 T3Nx T3Nx No treatment Don’t know‡ Surgery
E 51 F Oral Cavity TxN0 TxN0 TisN0 Surgery* Surgery* Surgery
F 36 M Oral Cavity TxNx T4aN0 T4aN0 Don’t know† Don’t know‡ Surgery
G 68 M Larynx TxNx T1N0 T1N0 Don’t know† Surgery Surgery
H 75 F Oral Cavity T1N2b T1N2b T1N2c Surgery Surgery Surgery
I 74 M Salivary Gland T2N0 T2N0 T2N0 Surgery Surgery Surgery
J 69 M Larynx T4aN1 T4aN2b T4aN1 Surgery Surgery Surgery
K 61 M Oral Cavity TxN0 T2N0 T2N0 Don’t know† Surgery Surgery
L 80 F Oral Cavity T2N0 T1N1 T2N2b Surgery Surgery Surgery
M 54 M Oropharynx TxN1 T1N1 T1N1 RT§ RT§ Surgery
N 82 F Oral Cavity T0N0 T0N0 T0N0 Don’t know‡ Don’t know‡ Surgery
O 49 F Oral Cavity T0N0 T1N0 T1N0 No treatment Don’t know‡ Surgery
P 70 M Larynx T4aN0 T4aN2c T4aN0 Surgery Surgery Surgery
Q 90 M Oral Cavity TxN1 T2N1 T2N1 Don’t know† Don’t know‡ Surgery
R 85 F NC & PNS TxN0 T4aN0 T4aN0 Don’t know† Don’t know◊ Surgery
S 56 M Oral Cavity TxN0 T4aN0 T4aN2b Surgery* Surgery Surgery
T 58 M Oral Cavity T4aNx T4aN2c T4aN1 Don’t know† Surgery Surgery
U 45 M Salivary Gland T1N0 T1N0 T1N0 Surgery Surgery Surgery
V 88 F Oral Cavity TxN1 T4aN1 T4aN1 Don’t know† Surgery Surgery
W 56 F Oral Cavity T0N0 TxN0 TisN0 No treatment Don’t know‡ Surgery
X 43 M Oropharynx TxN2a T2N2b T2N2b Don’t know† RT§ Surgery
Y 50 F Oral Cavity T1N0 T1N0 T1N0 Don’t know‡ Don’t know‡ Surgery
Z 81 M Oral Cavity TxN1 T2N2b T2N2b Don’t know† Surgery Surgery
AA 81 M Skin TxN2b TxN2b TxN2b Don’t know◊ Don’t know◊ Surgery
AB 58 F Oral Cavity T2N2b T2N2b T2N2b Don’t know‡ Don’t know‡ Surgery
AC 63 F Salivary Gland T3N0 T4aN2b T4aN1 Surgery Surgery Surgery
AD 65 M Oral Cavity TxN1 T2N2b T2N2b Don’t know† Surgery Surgery
F, Female; M, Male; NC & PNS, Nasal Cavity and Paranasal Sinuses; Pt, Patient Identifier; RT, Radiotherapy (+/−chemotherapy).
* Biopsy proven oral cavity cancer was stated in the Clinical History section of the report.
† Insufficient information in the report to make a recommendation.
‡ Technically inadequate or incomplete scan; the radiologist recommended additional imaging.
§ Oropharyngeal carcinoma is usually treated with primary radiotherapy (+/−chemotherapy) at our institution.
◊ Post-treatment recurrence; the surgeon needed details of prior treatment before making a salvage treatment decision.
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cancer domain, this was first reported by Loevner et al
[8]; the authors found a change in cancer stage in 34%
of cases and a change in management in 40% of patients
following expert radiologist reinterpretation. More
recently, Wheless et al [9] showed that, following case
review at a multidisciplinary head and neck tumor
board, 27% of patients had a change in tumor diagnosis,
stage, or treatment plan. In other oncological and non-oncological domains, studies of radiologist second opin-
ions have found discrepancy rates of 11–49% for diagno-
sis or staging and 7–37% for patient management
[10-16]. These rates are similar to those found for expert
second opinions in pathology, with reported discrepancy
rates of 7–66% (including changes from a benign to a
malignant diagnosis or vice versa) resulting in a change
in patient management in 1–28% [17-28]. There is much
less literature on the effect of expert second opinions in
Table 4 Accuracies of the original and second opinion
radiology reports compared to the pathologic staging
gold standard (n = 30)
Staging criteria Original report Second opinion
T-category 43.3% (27.4% − 60.8%) 93.3% (77.6% − 99.2%)
N-category 56.7% (39.2% − 72.6%) 70.0% (52.0% − 83.5%)
Stage (0-IV) 40.0% (24.6% − 57.7%) 93.3% (77.6% − 99.2%)
Low/High Stage 60.0% (42.3% − 75.4%) 96.7% (81.9% − 99.9%)
Node Negative/Positive 70.0% (52.0% − 83.5%) 86.7% (69.7% − 95.3%)
Data in parentheses are 95% confidence intervals.
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ancy rates for diagnosis and patient management of 35%
and 67%, respectively.
New insights into differences in biological behaviors of
head and neck cancers are leading to personalized treat-
ment options that are becoming increasingly diverse.
Parallel to this trend are advances in biologic imaging of
head and neck cancer that are used to select the most
appropriate treatment regimen for each individual pa-
tient [30]. As imaging techniques become more com-
plex, the frequency of clinically significant differences in
interpretation are expected to increase. Although a
change in diagnosis following subspecialist reinterpret-
ation of an imaging study does not necessarily imply a
correct change in diagnosis, “second opinion best reflects
a measure of diagnostic precision, which is a practical
surrogate for diagnostic accuracy, given the difficulties
of defining a gold standard” [31]. Thus, despite their
costs in terms of increased and often uncompensated
workload [2], it is likely that subspecialist secondFigure 1 Axial contrast enhanced CT images of the neck in an 81 yea
of a clinically enlarged right submandibular lymph node had shown s
0.5 cm in maximum thickness) enhancing mucosal lesion involving the righ
radiology report but was identified as the primary tumor in the second op
node (arrow) was interpreted as metastatic in both the original and second
asymmetrically prominent right level IIA lymph nodes (arrows) were not m
the second opinion report. Staging was TxN1 based on the original report
recommended management was ‘don’t know’ based on the original repor
and ‘surgery’ based on the second opinion report. Surgery was subsequenopinions will become increasingly important for high-
quality patient care.
In general radiology practice, where there is the usual
mixture of normal with abnormal cases, the discrepancy
rate is only 3% [32]. However, for patient populations
with 100% prevalence of disease, like those served by
multidisciplinary tumor boards at academic tertiary re-
ferral centers, the discrepancy rate can increase by an
order of magnitude [33]. The benefit of a subspecialist
model of radiology practice is highlighted by a recent
study [34] that showed the discrepancy rate between
fellowship-trained academic neuroradiologists was only
2% despite the high prevalence of disease (92%) in that
environment. A strength of the present study is that
each radiology report was independently analyzed for
staging information by three physician reviewers; an ex-
perienced fellowship-trained academic head and neck
surgeon, a senior otolaryngology-head and neck surgery
resident, and an experienced fellowship-trained aca-
demic neuroradiologist (a different neuroradiologist than
the one who had issued the second opinion reports).
The greater inter-rater agreement found for the second
opinion reports supports the assertion that imaging re-
interpretation by a subspecialist radiologist results in im-
proved diagnostic precision.
The weaknesses of the current study are its retrospect-
ive nonblinded design and the absence of a pathologic
gold standard in the nonsurgical cases. We chose a
retrospective design to decrease the potential bias of sec-
ondary gain by the reinterpreting neuroradiologist who,
if he knew his second opinion reports were to be subse-
quently scrutinized in a prospective study, might ber old male (Patient Z in Table 3); a fine needle aspiration biopsy
quamous cell carcinoma. (a) A plaque-like (2.5 cm in diameter ×
t retromolar trigone (arrow) was not mentioned in the original
inion report. (b) An enlarged (2.3 cm × 1.5 cm) right level IB lymph
opinion reports. (c) Two sub-centimeter but rounded and
entioned in the original report but were interpreted as metastatic in
and T2N2b (Oral Cavity) based on the second opinion report, and the
t (because the primary tumor location and T-category were unclear)
tly performed and the final pathologic staging was T2N2b (Oral Cavity).
Table 5 Differences in recommended management based on the original and second opinion radiology reports
Recommended
management
Based on second opinion report
Surgery RT No treatment Don’t know
Surgery 14 (14.9%) 1 (1.1%) 0 (0.0%) 1 (1.1%)
Based on original report RT 0 (0.0%) 15 (16.0%) 0 (0.0%) 1 (1.1%)
No treatment 1 (1.1%) 1 (1.1%) 1 (1.1%) 2 (2.1%)
Don’t know 16 (17.0%)* 12 (12.8%)† 1 (1.1%) 28 (29.8%)
RT, Radiotherapy (+/−chemotherapy).
* P < .001.
† P = .002.
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trade-off was to accept that the type of report (original
vs. second opinion) could not be adequately blinded to
the reviewers. Even if the name of the reporting radiolo-
gists and the location of the study were removed from
the reports, it would be clear, based on the content and
style of the report, which were second opinions. For ex-
ample, imaging findings or interpretations from the ori-
ginal radiology reports (both correct and incorrect), as
well as clinical information that might only be known at
the time of the second opinion, were routinely acknowl-
edged and discussed in the body of the second opinion
reports. It was therefore not possible to redact such
identifying information without substantially changing
the content of the reports. Because of this, it is possible
that the reviewers were biased to assign a greater degree
of certainty to information contained in reports they
knew to be second opinions. This would be expected to
be more of a problem for the patient management rec-
ommendation component of the study than for the can-
cer staging component and might, at least in part,
explain the relatively high frequency of ‘don’t know’ rec-
ommendations for the original reports. However, this
bias reflects the reality of clinical practice in which sub-
specialists may more frequently seek out additional in-
formation as is needed to provide a definitive opinion.
Arguably, therefore, blinding the reviewers in this way
would make the results less generalizable by inaccurately
reflecting routine practice. The randomized presentation
of the reports to the reviewers partially offsets this bias.
Establishing a gold standard for staging is difficult for
many head and neck cancers. Using surgical pathology
as the gold standard is problematic, as many patients do
not undergo surgery (e.g. some tumors are primarily
treated with radiotherapy) and, in those cases where sur-
gery is performed, pathologic staging might be incom-
plete (e.g. local tumor resection but no lymph node
dissection), inaccurate (e.g. is the muscle being infil-
trated by tumor on this slide an intrinsic or extrinsic
muscle of the tongue?), or insufficient (e.g. was there im-
paired vocal cord mobility or vocal cord fixation?). Even
in cases where complete and sufficient pathologicstaging information is available, it is only accurate at the
time of surgery and not at the time of the scan. However,
an error introduced by a scan-to-surgery delay would
apply equally to the original and second opinion reports
so, at minimum, the relative increase in accuracy found
for the second opinion reports in this study is valid.
Conclusion
More than one-half of patients with head and neck
cancer had a change in clinical stage following second
opinion review of their outside imaging studies by a
fellowship-trained academic neuroradiologist with ex-
pertise in head and neck imaging, and this led to a
change in management in greater than one-third of
patients. In patients with a biopsy proven or clinically
suspected malignancy, subspecialty radiologist inter-
pretation of imaging studies has a positive impact on
patient care.
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